المتخصصون في المجالات الطبية

تتوفر أدناه التجارب السريرية الحالية.

تصفية قائمة الدراسات هذه حسب الموقع، والحالة والمزيد.

1. RLY-2608-201-Ph2 Study Of RLY-2608 In PROS And PIK3CA Driven Malformations

   Rochester, Minn.

   The purpose of this study is to compare the efficacy and safety of RLY-2608 versus placebo in adult, adolescent, and pediatric participants with PROS and malformations driven by PIK3CA mutations, which is preceded by a dose selection and basket design with exploratory single-arm cohorts for various subpopulations of participants.

2. A Study to Establish a Pediatric Spine Registry

   Rochester, Minn., Minneapolis, Minn.

   The purpose of this study is to collect data about patients with chest wall and spinal deformities to develop a multicenter registry.  This will speed the pace of medical advancement and treatment recommendations for these conditions. 

3. CT Angiography of the Aorta following Fenestrated Branched Endovascular Aneurysm Repair (F-BEVAR) using Tube Potential Selection and Weight-based Method: Effects on Image Quality and Radiation Dose

   Rochester, Minn.

   The objective of this study is to evaluate the image quality and radiation dose of a CT angiography protocol (CTA) using tube potential selection and weight-based method.

4. A Study to Evaluate Endovascular Ablation of the Right Greater Splanchnic Nerve in Subjects Having Heart Failure with Preserved Ejection Fraction

   Rochester, Minn.

   The objective of this clinical evaluation is to assess the safety and initial effectiveness of catheter-based unilateral ablation of the right greater splanchnic nerve (GSN) in subjects having heart failure with preserved ejection fraction (HFpEF).

5. Comparison Of In-Home Versus In-Clinic Administration Of Subcutaneous Nivolumab Through Cancer CARE (Connected Access And Remote Expertise) Beyond Walls (CCBW) Program

   Jacksonville, Fla.

   This phase II trial compares the impact of subcutaneous (SC) nivolumab given in an in-home setting to an in-clinic setting on cancer care and quality of life. Currently, most drug-related cancer care is conducted in clinic type centers or hospitals which may isolate patients from family, friends and familiar surroundings for many hours per day. This separation adds to the physical, emotional, social, and financial burden for patients and their families. Traveling to and from medical facilities costs time, money, and effort and can be a disadvantage to patients living in rural areas, those with low incomes or poor access to transport. Studies have shown that cancer patients often feel more comfortable and secure being cared for in their own home environments. SC nivolumab in-home treatment may be safe, tolerable and/or effective when compared to in-clinic treatment and may reduce the burden of cancer and improve the quality of life in cancer patients.

6. Phase Ib Study of Axatilimab in Combination with Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

   Rochester, Minn.

   This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)

7. A Study of Endovascular Biopsy and Endothelial Cell Gene Analysis in Endovascular Procedures

   Rochester, Minn.

   The purpose of this study is to determine endothelial gene expression from guidewire biopsy during clinically indicated endovascular procedures. The genetic analysis will be measured against clinical outcomes and treatment response (response to non-coated and drug-coated technologies and different embolic agents depending on the procedure).

8. ALEX Study: A Randomized, Phase III Study Comparing Alectinib with Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Patients

   Scottsdale/Phoenix, Ariz.

   This randomized, active controlled, multicenter Phase III open-label study is designed to evaluate the efficacy and safety of alectinib compared with critozinib treatment in patients with treatment-naive ALK-positive advanced NSCLC. Patients will be randomized in a 1:1 ratio to receive either alectinib, 600 mg orally twice daily (BID), or critozinib, 250 mg orally BID. Patients will receive treatment until disease progression, unacceptable toxicity, consent withdrawal or death occurs. The study is expected to last approximately 42 months.

9. Study to Validate the Use of a Lymphatic Imaging Protocol to Stage Disease Severity in Patients with Lymphedema

   Jacksonville, Fla.

   The purpose of this study is to validate the use of a lymphatic imaging protocol to stage disease severity in patients with lymphedema and serve as a biomarker for microsurgical treatment response.

10. A Study of the Ability to Predict Lymphedema Development Following Axillary Surgery for Breast Cancer and Its Effects on Patient Survivorship

    Jacksonville, Fla.

    The purpose of this study is to better understand the anatomy of the lymphatic structure and the molecular process that leads to the over production of lymph fluid.  This proposal will begin intense lymphedema screening and identify baseline characteristics potentially predisposing someone to lymphedema, and identify molecular markers that might be altered to prevent lymphedema.